Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 rilzabrutinib versus placebo in adults with primary warm autoimmune hemolytic anemia
NL-OMON59086Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in warm autoimmune hemolytic anemia (wAIHA) comparing Rilzabrutinib with Placebo (2 arms). Primary endpoint: Durable hemoglobin response. Started Sep 2025; status: recruiting.
02
Drugs
rilzabrutinib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NL-OMON59086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59086.